[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 353
1. Markova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plütschow A, Eich HT, Dietlein M, Engert A, Kozak T: FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol; 2009 Jul;20(7):1270-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
  • BACKGROUND: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) in patients with advanced-stage HL.
  • PATIENTS AND METHODS: From January 2004 to March 2007, 50 patients with newly diagnosed HL in clinical stages IIB with large mediastinal mass or extranodal disease, III and IV were treated according to the HD15 protocol of the German Hodgkin Study Group.
  • CONCLUSION: Our results indicate a very good negative predictive value of PET-4 in advanced-stage HL patients treated with BEACOPP.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228806.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Gocheva L: Radiation therapy in Hodgkin's disease - decades of steady progress. J BUON; 2010 Apr-Jun;15(2):226-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy in Hodgkin's disease - decades of steady progress.
  • The improved therapeutic results for this disease group are included among the most important achievements of modern oncohaematology.
  • They are due to better disease staging, use of new markers for risk assessment, patient stratification in separate risk groups, implementation of highly effective chemotherapy (CHT), progress of targeted therapies using monoclonal antibodies, proteasome inhibitors, modern radiation therapy (RT) and supportive care.
  • The achieved progress, especially in the treatment of Hodgkin's disease (HD), is an example of the fundamental dependence of clinical practice on the scientific achievements, mainly in the field of diagnostics and in the two pure anticancer therapeutic modalities: chemo- and radiotherapy.
  • The aim of this article was to discuss the basic variants of RT in the multimodal treatment of HD and the clinical experience accumulated during the last decades.
  • Regardless of the already attained achievements of the combined treatment at the present stage of development of oncological knowledge, there is still no consensus with respect to the optimal therapy of HD in children and in adult patients.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658714.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 69
  •  go-up   go-down


3. Kanat O, Ozet A, Ataergin S, Arpaci F, Kuzhan O, Komurcu S, Ozturk B, Ozturk M: Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma. Med Princ Pract; 2010;19(5):344-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma.
  • OBJECTIVE: Our purpose was to investigate the efficacy of and establish a toxicity profile for a modified regimen of dexamethasone, cytarabine and cisplatin (DHAP) for lymphoma outpatients.
  • SUBJECTS AND METHODS: Fifty-one lymphoma patients, 26 with Hodgkin's disease and 25 with non-Hodgkin's lymphoma, were included.
  • Twenty had progressive/refractory disease and 31 relapsed disease.
  • Twenty-five were in clinical stage I/II and 26 in clinical stage III/IV before the initiation of salvage chemotherapy.
  • The overall response rate (85% for Hodgkin's disease and 95% for non-Hodgkin's lymphoma) was 88.3% (39.2% complete response and 49.1% partial response).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Outpatients
  • [MeSH-minor] Adolescent. Adult. Cisplatin / adverse effects. Cisplatin / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20639655.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


Advertisement
4. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


5. Knecht H, Sawan B, Lichtensztejn Z, Lichtensztejn D, Mai S: 3D Telomere FISH defines LMP1-expressing Reed-Sternberg cells as end-stage cells with telomere-poor 'ghost' nuclei and very short telomeres. Lab Invest; 2010 Apr;90(4):611-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3D Telomere FISH defines LMP1-expressing Reed-Sternberg cells as end-stage cells with telomere-poor 'ghost' nuclei and very short telomeres.
  • In Epstein-Barr virus (EBV) negative Hodgkin's cell lines and classical EBV-negative Hodgkin's lymphoma (HL), Reed-Sternberg cells (RS cells) represent end-stage tumor cells, in which further nuclear division becomes impossible because of sustained telomere loss, shortening and aggregation.
  • We performed a 3D telomere analysis after quantitative fluorescent in situ hybridization on 5 mum tissue sections on two LMP1-expressing HL cases and showed highly significant telomere shortening (P<0.0001) and formation of telomere aggregates in RS cells (P<0.0001), when compared with the mononuclear precursor Hodgkin cells (H cells).
  • We conclude that RS cells irrespective of LMP1 expression are end-stage tumor cells in which the extent of their inability to divide further is proportional to the increase of very short telomeres, telomere loss, aggregate formation and the generation of 'ghost' nuclei.
  • [MeSH-major] Hodgkin Disease / genetics. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Female. Humans. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Male. Viral Matrix Proteins / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142802.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


6. Fuertes Manuel J, Estorch Cabrera M, Camacho Martí V, Flotats Giralt A, Rodríguez-Revuelto AA, Hernández Fructuoso MA, Carrió Gasset I: [SPECT-CT 67Ga studies in lymphoma disease. Contribution to staging and follow-up]. Rev Esp Med Nucl; 2006 Jul-Aug;25(4):242-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [SPECT-CT 67Ga studies in lymphoma disease. Contribution to staging and follow-up].
  • The aim of this study is to evaluate advantages of 67Ga SPECT-CT study over planar, SPECT and high resolution CT studies in lymphoma disease.
  • Thirty-eight patients (51 %) were diagnosed of Hodgkin's lymphoma and 36 were non-Hodgkin's lymphoma.
  • These findings changed the disease stage 18 times (18 % of whole studies).
  • 67Ga SPECT-CT study improves the diagnostic yield of the study with 67Ga in patients with lymphoma, providing better anatomical localization of tumoral lesions and detection of extraganglionar disease.
  • [MeSH-major] Gallium Radioisotopes. Hodgkin Disease / radiography. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Neoplasm Staging / methods. Radiopharmaceuticals. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes / radiography. Lymph Nodes / radionuclide imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827987.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals
  •  go-up   go-down


7. Ng AK, Li S, Neuberg D, Fisher DC, McMillan C, Silver B, Marcus KC, Stevenson MA, Mauch PM: Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease. Ann Oncol; 2006 Nov;17(11):1693-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease.
  • BACKGROUND: To determine the long-term treatment outcome and late effects of mantle irradiation alone in selected patients with early-stage Hodgkin's disease.
  • METHODS: Between 1988 and 2000, 87 patients with pathologic stage (Ann Arbor) I-IIA or clinical stage IA Hodgkin's disease were entered on to a prospective trial of mantle irradiation alone.
  • All 13 patients who relapsed are alive without evidence of disease at a median of 84 months (range 30-156) post-salvage therapy.
  • CONCLUSION: In selected patients with early-stage Hodgkin's disease, mantle irradiation alone has an excellent long-term survival rate, comparing favorably with the previous standard treatment of extended-field radiation therapy and the current standard of combined modality therapy.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018702.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Kharchenko VP, Datsenko PV, Panyshin GA, Sotnikov VM, Mel'nik IuD: [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis]. Vopr Onkol; 2006;52(5):531-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis].
  • Data are presented on our 5-year experience with combination chemotherapy of stage II-IV Hodgkin's disease (110), the unfavorable prognosis group, using a novel regimen of chemotherapy--CEA/ABVD (belustin, etoposide, doxorubicin, bleomycin, vinblastine, dacarbazine).
  • Our regimen opens up new vistas in managing Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168361.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; ABVD protocol; CEA protocol
  •  go-up   go-down


9. van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group: Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol; 2005 Jun 1;23(16):3793-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
  • PURPOSE: Timing, appropriate amount, and composition of treatment before high-dose therapy and autologous stem-cell transplantation (ASCT) in patients with poor-risk, aggressive non-Hodgkin's lymphoma (NHL) are still unknown.
  • PATIENTS AND METHODS: Between 1994 and 2001, 147 newly diagnosed, poor-risk, aggressive NHL patients, age < or = 65 years with stage III to IV and lactate dehydrogenase (LDH) more than 1.5x upper limit of normal (ULN), entered the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) -27 and HOVON-40 trials.
  • RESULTS: Patient characteristics in both trials were comparable: 80% had diffuse large B-cell lymphoma, 77% had stage IV disease, and median LDH levels were 3.1x ULN.
  • Four-year survival estimates in HOVON-27 compared with HOVON-40 were overall survival, 21% v 50% (P = .007); event-free survival, 15% v 49% (P = .0001); and disease-free survival, 34% v 74% (P = .008).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Stem Cell Transplantation. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809447.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Campbell B, Wirth A, Milner A, Di Iulio J, MacManus M, Ryan G: Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1538-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
  • PURPOSE: To evaluate the long-term results of salvage radiotherapy (SRT) for Hodgkin's lymphoma after chemotherapy failure.
  • METHODS AND MATERIALS: We reviewed 81 patients undergoing SRT for persistent or recurrent Hodgkin's lymphoma after chemotherapy; 19 also received conventional-dose salvage chemotherapy.
  • Of the 81 patients, 81% had Stage I-II, 25.9% had B symptoms, 14.8% had bulky disease, and 7.4% had extranodal disease.
  • The adverse prognostic factors for freedom from treatment failure were age >50 years (p < 0.001), B symptoms (p < 0.001), extranodal disease (p = 0.012), and less than a CR to the last chemotherapy regimen (p = 0.001).
  • CONCLUSIONS: Salvage radiotherapy is effective for selected patients with Hodgkin's lymphoma after chemotherapy failure and should be considered for incorporation into salvage programs.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Child, Preschool. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Recurrence. Sex Factors. Treatment Failure. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125872.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


11. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, Todisco E, Bramanti S, Mazza R, Russo F, Timofeeva I, Santoro A: Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Hematol; 2007 Feb;82(2):122-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
  • We designed a prospective study to evaluate the feasibility and efficacy of tandem high-dose chemotherapy (HDCT) in the treatment of refractory or relapsed Hodgkin's lymphoma (HL).
  • In an intention-to-treat analysis, the overall response rate increased after each stage of protocol, ranging from 47% to 65% and 75% after IGEV, MEL200, and BEAM, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Cytarabine / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Prospective Studies. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17019686.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; Q6C979R91Y / vinorelbine; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; BEAM protocol
  •  go-up   go-down


12. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW: Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2006 Sep;12(9):965-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
  • High-dose chemotherapy followed by blood or marrow transplantation (BMT) is generally considered the best salvage option for patients with relapsed diffuse large-B-cell non-Hodgkin's lymphoma (DLCL).
  • The allo-BMT recipients had a higher proportion of patients with chemoresistant disease (P = .004) and had received more chemotherapy before BMT (P = .02).
  • The auto-BMT recipients were older (P < .001) and were of more advanced-stage disease (P = .01).
  • The 3-year OS for patients with sensitive disease was 51.9% after allo-BMT and 46.2% after auto-BMT (log-rank, P = .38).
  • For patients with resistant disease, the 3-year OS was 12.1% after allo-BMT and 19.1% after auto-BMT (log rank, P = .08).
  • In multivariate analysis, significant predictors of death were disease sensitivity (hazard rate [HR], 0.3; 95% confidence interval [CI] 0.2-04; P < .001), age >40 years (HR, 2.42; 95% CI, 1.7-3.4; P < .001), and stage at diagnosis (HR, 1.2; 95% CI, 1.0-1.4; P = .04).
  • The 3-year event-free survival (EFS) for patients with sensitive disease was 52.7% after allo-BMT and 42.0% after auto-BMT (log-rank, P = .29).
  • For patients with resistant disease, the 3-year EFS was 6.2% after allo-BMT and 19.4% after auto-BMT (log-rank, P = .1).
  • The 3-year relapse rate in patients with resistant disease was 75.0% after allo-BMT and 69.9% after auto-BMT (log-rank, P = .58).
  • In multivariate analysis, only disease sensitivity status (HR, 0.4; 95% CI, 0.2-2.1; P < .001) and age >40 years (HR, 1.7; 95% CI, 1.1-2.9; P = .03) appear to have a significant impact on relapse.
  • Mortality from lymphoma was 26.6% in allo-BMT recipients and 43.5% in auto-BMT recipients (P = .02).
  • For patients with sensitive disease, allo-BMT seemed to provide longer survival with less relapse; however, this was achieved at the cost of greater TRM.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920563.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, Endler G, Rumpold H, Agis H, Sillaber C, Jäger U, Valent P: Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest; 2009 Oct;39(10):914-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We have determined serum tryptase levels in 914 patients with haematological malignancies, including myeloproliferative disorders (n = 156), myelodysplastic syndromes (MDS, n = 241), acute myeloid leukaemia (AML, n = 317), systemic mastocytosis (SM, n = 81), non-Hodgkin's lymphoma (n = 59) and acute lymphoblastic leukaemia (n = 26).
  • In most patients with non-neoplastic haematological disorders and non-haematological disorders analysed in our study, tryptase levels were normal, the exception being a few patients with end-stage kidney disease and helminth infections, in whom a slightly elevated tryptase was found.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Middle Aged. Tryptases / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522836.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


14. Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, Shimoni A, Nagler A, Ben-Bassat I, Polliack A: Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol; 2010 Jan;21(1):126-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
  • BACKGROUND: Escalated combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (escBEACOPP) regimen is superior to cyclophosphamide, vincristine, procarbazine and prednisone alternating with doxorubicin, bleomycin, vinblastine and dacarbazine (COPP-ABVD) for advanced-stage Hodgkin's lymphoma (HL) patients.
  • PATIENTS AND METHODS: Forty-five newly diagnosed patients with advanced-stage HL and International Prognostic Score > or = 3 received two initial cycles of escBEACOPP and then were evaluated by positron emission tomography (PET)/computed tomography scan.
  • RESULTS: Following the first two cycles of escBEACOPP, the overall response was 100% and at the end of all therapy, 40 (89%) patients were in complete response (disappearance of all clinical evidence of disease and PET negativity), three (7%) in partial response (PET-positive residual lesions and a size reduction of the majority of large masses by >50%), while two (4%) had progressive disease.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19608615.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


15. Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M, EORTC-GELA H8 Trial Group: Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol; 2009 Dec;10(12):1160-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
  • BACKGROUND: Little is known about the longitudinal course of health-related quality of life (HRQoL) in patients with Hodgkin's lymphoma during their post-treatment follow-up and re-adaptation to normal life.
  • We report on the HRQoL of patients treated in the randomised H8 trial of the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
  • INTERPRETATION: HRQoL data after treatment for early-stage Hodgkin's lymphoma show that patients experience strain and limitations in all subdomains apart from cognitive functioning (QLQ-C30), and also have reduced motivation (MFI-20).
  • [MeSH-major] Hodgkin Disease / psychology. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Dec;10(12):1134-5 [19959071.001]
  • (PMID = 19828373.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00379041
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Salem HA, Eissa LA, Rabbie AM, El-Helw LM, El-Gayar AM: Evaluation of some biochemical markers as prognostic factors in malignant lymphomas. Pak J Pharm Sci; 2006 Jul;19(3):219-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage.
  • For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital.
  • Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV.
  • RESULTS: 1-Pre-treatment levels of GAGs, sp55TNF-R and sL-selectin increased significantly in both HD and NHL before treatment as compared to control.
  • Pre-treatment sp55TNF-R levels in both diseases and sL-selectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sL-selectin in NHL patients had a limited value in such prediction.
  • 2- In contrast to sp55TNF-R and sL-selectin, post-treatment GAG levels are thought to be a good sign of remission in both HD and NHL.
  • 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • CONCLUSION: Pre-treatment sp55TNF-R levels in both HD & NHL and sL-selectin (only in HD patients) could be used as prognostic factor with respect to predicting treatment outcome.
  • Serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • [MeSH-major] Biomarkers, Tumor. Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Blood Cell Count. Blood Sedimentation. Female. Glycosaminoglycans / metabolism. Humans. Kidney Function Tests. L-Lactate Dehydrogenase / metabolism. L-Selectin / metabolism. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Tumor Necrosis Factor, Type I / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935830.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycosaminoglycans; 0 / Receptors, Tumor Necrosis Factor, Type I; 126880-86-2 / L-Selectin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


17. Papaxoinis G, Fountzilas G, Rontogianni D, Dimopoulos MA, Pavlidis N, Tsatalas C, Pectasides D, Xiros N, Economopoulos T: Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol; 2008 Apr;19(4):780-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).
  • BACKGROUND: The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Epidemiological and clinical features of 97 patients with MALT lymphoma from the Hellenic Cooperative Oncology Group registry were analysed retrospectively for their prognostic significance in progression-free survival (PFS) and overall survival (OS).
  • Comparisons were made between patients with gastric and nongastric sites of primary lymphoma and between different therapeutic modalities.
  • Seventy-four per cent of patients had early (Ann Arbor stages I-II) and 26% had advanced (stages III-IV) disease.
  • The most reliable prognostic factor for PFS and OS was the Ann Arbor stage; 5-year PFS was 67% versus 13% and 5-year OS 91% versus 51% for patients with early versus advanced disease, respectively (P < 0.001).
  • Surgery did not offer survival benefit compared with chemotherapy in localised gastric lymphoma.
  • CONCLUSION: MALT lymphomas represent a distinct disease entity with widespread extranodal origin, indolent clinical course and high chemosensitivity.
  • Ann Arbor stage was the most reliable prognostic and predictive factor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156143.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


18. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma; 2006 Apr;47(4):641-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.
  • Advanced-stage or relapsed/refractory Hodgkin's disease (HD) has a poor prognosis despite aggressive chemotherapy regimens and the use of high-dose therapy with autologous stem cell support.
  • Mitoxantrone, vinblastine and CCNU (lomustine) (MVC) combines the most effective chemotherapeutic agents of previous regimens for poor prognosis HD, and eliminates marginally active agents with unnecessary toxicities, such as bleomycin and dacarbazine.
  • Sixty-eight patients with HD (23 newly diagnosed and 45 with relapsed/refractory disease, one patient treated both de novo and years later in relapse) were treated with the MVC regimen (mitoxantrone 8 mg/m(2)/day i.v. days 1 - 3; vinblastine 8 m/m(2)/day days 1 and 22; and CCNU (lomustine) 100 mg/m(2) on day 1, repeated at 6 - 8 weeks) in a single-arm Phase II study.
  • MVC regimen for HD is highly active, for both de novo and relapsed/refractory disease, with high response rates and survival that compare favourably with the results obtained by high-dose therapy with stem-cell transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lomustine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Vinblastine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690523.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA14958; United States / NCI NIH HHS / CA / P30CA13330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


19. Tan WY, Hu DS, Zeng FY, Song QB, Hu S, Wei L, Zhou LQ: [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases]. Ai Zheng; 2007 Dec;26(12):1360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
  • BACKGROUND & OBJECTIVE: The treatment strategies of Hodgkin's lymphoma (HL) are different according to clinical stage and risk factors, yet the optimal treatment strategy remains unclear.
  • This study was to analyze the treatment results and prognostic factors of stage IA HL.
  • METHODS: According to prognosis, 97 patients with stage IA HL were divided into 3 groups: 7 (7.2%) in very favorable (VF) group, 72 (74.2%) in favorable (F) group, and 18 (18.6%) in unfavorable (UF) group.
  • The 5-and 10-year overall survival (OS) rates were 87.7% and 76.3%; the 5-and 10-year disease-free survival (DFS) rates were 79.4% and 74.5%.
  • The occurrence rate of secondary malignancies was 5.2%, including 2 cases of non-Hodgkin's lymphoma.
  • CONCLUSIONS: More than 90% of stage IA HL patients can achieve CR with radiotherapy alone or chemoradiotherapy.
  • The pathologic type, response to primary treatment and tumor relapse may be independent prognostic factors of stage IA HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076802.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; MOPP protocol
  •  go-up   go-down


20. Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR: Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2009 Mar;135(3):459-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
  • INTRODUCTION: Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL).
  • Consolidating involved-field irradiation was applied in patients with stage I/II, bulky disease, or localized residual lymphoma.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal / toxicity. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Remission Induction. Rituximab. Survival Analysis. Survivors. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):257-67 [8558207.001]
  • [Cites] Ann Intern Med. 1990 Oct 15;113(8):619-27 [2205142.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1067-73 [11583187.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3722-7 [3458531.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):536-41 [16098067.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1864-71 [15143078.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2070-9 [9626206.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):277-81 [12562656.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2912-9 [16339404.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):93-101 [17313557.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):409-16 [18038870.001]
  • [Cites] Ann Oncol. 1993 May;4(5):359-69 [8353070.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 18758815.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Ho CL, Hsieh AT, Dai MS, Chen YC, Kao WY, Chao TY: Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period. J Chin Med Assoc; 2005 Jan;68(1):11-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period.
  • BACKGROUND: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment.
  • METHODS: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage 1, 17 stage II, two stage III, and nine stage IV.
  • The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6).
  • The 11 stage III/IV patients received CT and/or RT with regimens similar to those for stage I/III patients.
  • The 5-year survival rates for stage 1, II and III/IV patients were 57.2%, 47% and 0%, respectively (p < 0.005).
  • Of the 24 surgical patients (group A) who received sequential CT, with or without RT, 12 remained disease-free after a median follow-up of 98 months (range, 1-210 months); three patients died because of postoperative complications.
  • Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT.
  • All stage III and IV patients died after a median survival of 4 months (range, 1-8 months).
  • CONCLUSION: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL.
  • In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Stomach / pathology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742857.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


22. Bairey O, Blickstein D, Monselise Y, Lahav J, Stark P, Prokocimer M, Nativ HM, Kirgner I, Pazgal I, Shaklai M: Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma. Eur J Haematol; 2006 May;76(5):384-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
  • The aim of this study was to determine the prevalence of IgG, IgM, and IgA anticardiolipin antibodies (aCL) and anti-beta-2 glycoprotein I antibodies (anti-beta2-GPI) in patients with non-Hodgkin's lymphoma (NHL), and to investigate their clinical and prognostic significance.
  • There was no significant correlation between elevated APA levels and patient's age or sex, disease stage or grade, bone marrow involvement, B symptoms, serum lactate dehydrogenase levels, serum beta2 microglobulin levels, International Prognostic Index (IPI) score, performance status, type of treatment, or response to treatment.
  • There was a correlation between elevated APA and absence of extranodal disease (P = 0.045).
  • [MeSH-major] Antibodies, Antiphospholipid / blood. Autoantibodies / blood. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Anticardiolipin / blood. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Glycoproteins / immunology. Humans. Lupus Coagulation Inhibitor / blood. Male. Middle Aged. Partial Thromboplastin Time. Prognosis. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Treatment Outcome. beta 2-Glycoprotein I

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466368.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Glycoproteins; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I
  •  go-up   go-down


23. Valsami S, Pappa V, Rontogianni D, Kontsioti F, Papageorgiou E, Dervenoulas J, Karmiris T, Papageorgiou S, Harhalakis N, Xiros N, Nikiforakis E, Economopoulos T: A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica; 2007 Oct;92(10):1343-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4.
  • BACKGROUND AND OBJECTIVES: Although most patients with classical Hodgkin's lymphoma (CHL) are cured, a significant minority are refractory to treatment.
  • Univariate analysis showed that age of 45 or more, stage III and IV disease and MUM/IRF4 negative status were associated with significantly shorter time to progression (TTP) and overall survival (OS).
  • On multivariate analysis the lack of MUM/IRF4 expression was associated with significantly shorter TTP while age of 45 or more and the presence of extralymphatic sites of disease were associated with significantly shorter OS.
  • [MeSH-major] Cell Differentiation. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Interferon Regulatory Factors / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Transcription Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768115.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interferon Regulatory Factors; 0 / Transcription Factors; 0 / interferon regulatory factor-4
  •  go-up   go-down


24. Hsieh PP, Tseng HH, Chang ST, Fu TY, Lu CL, Chuang SS: Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan. Leuk Lymphoma; 2006 Jan;47(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan.
  • Primary non-Hodgkin's lymphoma of bone (PLB) is a rare disorder representing less than 1% of all non-Hodgkin's lymphomas and has rarely been reported in Taiwan.
  • The staging results were stage I (9 patients, 64%), stage II (2, 14%) and stage IV (3, 21%).
  • Of the 11 patients with follow-up information, 6 (55%) died of disease within 1 year including 5 with T-cell lymphomas, while all the 5 patients surviving over 1 year were of B-cell phenotype.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Lineage. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Phenotype. Predictive Value of Tests. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, Vitolo U, Mancini M, Bisi G, Gallo E: Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med; 2008 Jun;113(4):578-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
  • PURPOSE: The aim of this study was to evaluate the role of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the staging of Hodgkin's and aggressive non-Hodgkin's lymphoma (HL and NHL), comparing it with conventional diagnostic methods, i.e. contrast-enhanced CT and bone marrow biopsy.
  • MATERIALS AND METHODS: Sixty-five consecutive patients (30 HL and 35 NHL) who underwent conventional disease staging and FDG-PET/CT were included.
  • Concordance between conventional methods and PET was established when both procedures identified the same disease stage.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnostic imaging. Lymphoma, Non-Hodgkin / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity


26. Batuecas Caletrío A, Gómez González JL, Muñoz Herrera A, Blanco Pérez P, Serradilla López JM, Gil Melcón M, Ocio San Miguel EM: [Non Hodgkin's lymphoma in the ENT field]. Acta Otorrinolaringol Esp; 2005 May;56(5):215-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in the ENT field].
  • [Transliterated title] Linfomas no Hodgkin en patología cérvico-facial.
  • OBJECTIVES: Non Hodgkin's lymphoma (NHL) is a frecuent tumor in the ENT field althougt there are not too many publications with a large number of patients.
  • PATIENTS AND METHODS: We have studied 300 patiens with NHL and analysed the head and neck affectation, the presence in Waldeyer's ring, the first symptoms and the stage of the disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Otorhinolaryngologic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960125.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Rueda A, Olmos D, Viciana R, Alba E: Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment. Clin Lymphoma Myeloma; 2006 Mar;6(5):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment.
  • BACKGROUND: Doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) chemotherapy alone is a viable option for the treatment of stage I/II Hodgkin's lymphoma.
  • Among the main drawbacks for widespread acceptance of this therapy is the absence of available data on the post-salvage therapy course in patients with limited-stage disease who relapse after ABVD.
  • This article focuses on the outcome of 11 limited-stage patients who relapsed after ABVD alone.
  • PATIENTS AND METHODS: After a clinical restaging, the patients received mantle-type radiation therapy (only if patients met these criteria: supradiaphragmatic disease in a single-node area, erythrocyte sedimentation rate < 30 mm per hour, and absence of B symptoms) or conventional salvage chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
  • RESULTS: After a median follow-up of 64 months, 10 patients showed complete response and are still alive without disease progression.
  • One patient showed refractory disease and died 9 months after relapse.
  • This experiment entails the series with the longest follow-up in patients with limited-stage Hodgkin's lymphoma who relapsed after ABVD alone.
  • [MeSH-major] Cause of Death. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Bleomycin. Cohort Studies. Combined Modality Therapy. Dacarbazine. Doxorubicin. Female. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Humans. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Vinblastine

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640815.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


28. He YF, Zhang YJ, Li YH, Lin TY, Xia YF, Lu TX, Huang HQ, Jiang WQ, Xian CG, He YJ, Guan ZZ: [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases]. Ai Zheng; 2006 Dec;25(12):1538-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
  • BACKGROUND & OBJECTIVE: Primary non-Hodgkin's lymphoma (NHL) of the nasal cavity has unique clinicopathologic features, and optimal treatment regimen remains unclear.
  • This study was to summarize the clinical features, treatment outcomes, and prognostic factors of primary NHL of the nasal cavity at early stage.
  • Pre-treatment history of disease, extent of primary lesion involvement, and response to the primary treatment may be independent prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Nasal Cavity. Nose Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Proportional Hazards Models. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166382.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


29. Rygoł B, Kyrcz-Krzemień S, Pajiak J, Konicki P, Kowai E, Gasińska T: [Tryptase- and chymase-positive mast cells as possible prognostic factor in patients with Hodgkin's lymphoma]. Pol Arch Med Wewn; 2007 Jan-Feb;117(1-2):27-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tryptase- and chymase-positive mast cells as possible prognostic factor in patients with Hodgkin's lymphoma].
  • Aim of the study was to reveal potential prognostic factors in Hodgkin's lymphoma (HL) patients by means of assessment of the influence of mast cells on clinical characteristics of the disease.
  • PATIENTS AND METHODS: Paraffin-fixed lymph node biopsies taken from the group of 72 patients treated for Hodgkin's lymphoma in the Department of Internal Medicine and Oncological Chemotherapy of Silesian Medical Academy in Katowice from 1990 to 2002.
  • Overall survival (OS) for the group ranged from 3 to 169 month (mean 64.5) while disease-free survival (DFS) was from 4 to 167 months (mean 44.8).
  • Despite the fact that increased density of MCD-T and MCD-T was observed in stage III and the lowest in stage IV of the disease, no correlation was found between MCD and stage, sex or age.
  • CONCLUSIONS: Tryptase and chymase-positive mast cell density is related to histological type of Hodgkin's lymphoma.
  • [MeSH-major] Biomarkers, Tumor. Chymases / metabolism. Hodgkin Disease / enzymology. Hodgkin Disease / mortality. Mast Cells / enzymology. Tryptases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis. Disease-Free Survival. Humans. Immunohistochemistry. Lymph Nodes / cytology. Lymph Nodes / enzymology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642203.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


30. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol; 2010 Feb 10;28(5):793-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
  • PURPOSE Prior observations suggest a higher risk of transformation of nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), than in classical Hodgkin's lymphoma.
  • Results Patients with NLPHL had the following characteristics at diagnosis: median age of 37 years, 73% male, and 68% stage I or II disease.
  • With a median follow-up time for living patients of 6.5 years (range, 2.5 to 33 years), 13 patients (14%) experienced transformation to aggressive lymphoma (median time to transformation, 8.1 years; range, 0.35 to 20.3 years).
  • The actuarial risk of transformation to aggressive lymphoma was 7% and 30% at 10 and 20 years, respectively.
  • The 10-year progression-free and overall survival rates in patients with transformed lymphoma were 52% and 62%, respectively.
  • [MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Second Primary
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. British Columbia / epidemiology. Databases as Topic. Disease Progression. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Altamirano J, Esparza JR, de la Garza Salazar J, Calvo PS, Vera SR, Chalapud Revelo JR, Estrada G: Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Arch Med Res; 2008 Jan;39(1):69-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We undertook this study to determine the diagnostic accuracy of (18)FDG after three cycles and at the end of chemotherapy in non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL).
  • We also evaluated the role of (67)Ga, bone marrow aspiration (BMA), and computed tomography (CT) in monitoring lymphoma treatment.
  • Histopathology considered the standard reference at the initial stage.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067998.001).
  • [ISSN] 0188-4409
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Ypma PF, Wijermans PW, Koppen H, Sillevis Smitt PA: Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma. Neth J Med; 2006 Jul-Aug;64(7):243-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma.
  • PCD can accompany different kinds of neoplasms including small cell lung cancer, adenocarcinoma of the breast and ovary, and Hodgkin's lymphoma.
  • The search for Hodgkin's disease as concomitant disorder was then started and resulted in stage II B disease.
  • The patient was successively treated with six courses of etoposide, bleomycin, vinblastine and dexamethasone and radiotherapy, which resulted in a complete remission of the Hodgkin's disease.
  • Improvement of the cerebellar syndrome in anti-Tr autoantibody paraneoplastic disease is a rare achievement.
  • Early recognition of the concomitant disorders (anti-Tr autoantibody disease and Hodgkin's lymphoma) is of crucial importance.
  • [MeSH-major] Cerebellum / pathology. Hodgkin Disease / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoplasm Staging. Positron-Emission Tomography. Radiotherapy, Adjuvant. Remission Induction. Tomography, X-Ray Computed. Vinblastine / administration & dosage


33. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


34. Nicotra G, Manfroi F, Follo C, Castino R, Fusco N, Peracchio C, Kerim S, Valente G, Isidoro C: High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome. Dis Markers; 2010;28(3):167-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome.
  • We investigated whether the level of CD expression influences the progression and the clinical outcome in Non-Hodgkin's Lymphomas (NHLs).
  • Lymphomas highly expressing CD were associated with a worse stage (III-IV) at diagnosis (31/34 cases; p=0.002) and with a poor clinical outcome (i.e., partial remission and death; 28/34 cases; p=0.03).
  • In Cox multivariate analysis CD failed to be a prognosticator independent of pathologic stage, though the hazard ratio confirmed the association of low expression with a better survival probability.
  • [MeSH-major] Cathepsin D / metabolism. Lymphoma, Non-Hodgkin / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534902.001).
  • [ISSN] 1875-8630
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.23.5 / Cathepsin D
  • [Other-IDs] NLM/ PMC3833244
  •  go-up   go-down


35. Lee MY, Tan TD, Feng AC: Clinico-pathological study of Hodgkin's lymphoma in a cancer center in Taiwan. Clin Lab Haematol; 2005 Dec;27(6):379-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological study of Hodgkin's lymphoma in a cancer center in Taiwan.
  • The incidence rate of Hodgkin's lymphoma (HL) in Asia is much lower than that of western countries.
  • The incidence rate of HL in malignant lymphoma in our center was 7%.
  • Clinically, 1 (2%) had stage I disease, 23 (55%) stage II, 8 (19%) stage III and 10 (24%) stage IV.
  • Two cases had rare primary bone marrow HL of stage IV.
  • Clinical stage (P=0.09) and age (P<0.001) were prognostic parameters determining the overall survival.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Cancer Care Facilities. Child. Female. Humans. Incidence. Lymphocytes / pathology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Prognosis. Sclerosis. Survival Analysis. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307539.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Makinson A, Martelli N, Peyrière H, Turriere C, Le Moing V, Reynes J: Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol; 2007 Apr;78(4):358-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease.
  • A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia.
  • [MeSH-major] Anti-HIV Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Neutropenia / chemically induced. Vinblastine / adverse effects
  • [MeSH-minor] Adult. Humans. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378895.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


37. Page E, Assouline D, Durand C, Brun O, Coeffic D, Fric D, Garnier C, Leyronnas C, Alcalay V, Aguilaniu B: Stage-related changes in functional capacity in Hodgkin's disease: assessment by cardiopulmonary exercise testing before initiation of treatment. Ann Hematol; 2006 Dec;85(12):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-related changes in functional capacity in Hodgkin's disease: assessment by cardiopulmonary exercise testing before initiation of treatment.
  • Our aim was to examine indices of cardiorespiratory capacity at rest and during exercise before initiation of therapy for Hodgkin's disease.
  • We prospectively studied 24 patients divided into two groups according to the disease stage.
  • Group 1 included eight patients in stage IA and four in stage IIA; group 2 included four patients in stage IIB, six in stage III, and two in stage IV.
  • Functional capacity during exercise was markedly reduced in patients suffering from Hodgkin's disease in advanced stages.
  • [MeSH-major] Cardiovascular Physiological Phenomena. Exercise Tolerance / physiology. Hodgkin Disease / physiopathology. Lung / physiopathology
  • [MeSH-minor] Adult. Echocardiography. Electrocardiography. Exercise Test. Female. Humans. Male. Neoplasm Staging. Pulmonary Diffusing Capacity. Vital Capacity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969675.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Hines-Thomas MR, Howard SC, Hudson MM, Krasin MJ, Kaste SC, Shulkin BL, Metzger ML: Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica; 2010 Oct;95(10):1691-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma.
  • BACKGROUND: Bone marrow biopsy is considered essential for the staging and risk-adapted treatment of Hodgkin's lymphoma with unfavorable risk features.
  • We reviewed the cases of pediatric Hodgkin's lymphoma in our institution to determine the impact of bone marrow involvement on treatment, relapse, and survival.
  • DESIGN AND METHODS: We reviewed the clinical characteristics and outcome of 383 patients treated for Hodgkin's lymphoma at St. Jude Children's Research Hospital between August 1990 and August 2008.
  • Bone marrow findings changed the disease stage in only seven patients (3.1%): from IB to IVB (n=1), from IIA (with bulky disease) to IVA (n=1), from IIB to IVB (n=1), and from IIIB to IVB (n=4).
  • No statistically significant difference was observed between patients with stage IV Hodgkin's lymphoma who did (n=21) and did not (n=61) have bone marrow involvement in 5-year relapse-free survival (89.6± 7% versus 73.9±6.1%; P=0.25) or 5-year overall survival (95.2±8.2% versus 87.3±4.9%; P=0.82).
  • CONCLUSIONS: Although bone marrow involvement changed the stage in 3.1% of pediatric Hodgkin's lymphoma patients, it did not change risk-adapted treatment or prognosis.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2002 Nov;119(2):408-11 [12406078.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):150-6 [15175959.001]
  • [Cites] N Engl J Med. 1968 May 23;278(21):1179 [5646722.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1733-6 [5121677.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Br J Haematol. 1982 Jul;51(3):345-60 [7104222.001]
  • [Cites] Eur J Haematol. 1987 Jul;39(1):66-70 [3653373.001]
  • [Cites] Eur J Haematol. 1988 Oct;41(4):359-67 [3197822.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1971-80 [1700080.001]
  • [Cites] Chest. 1991 Mar;99(3):784-5 [1995250.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1591-8 [1714950.001]
  • [Cites] Acta Oncol. 1992;31(1):41-2 [1586503.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):241-55 [7926973.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):403-9 [7844601.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):171-6 [9250802.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):175-7 [9434827.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):603-9 [9469348.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):897-906 [9508171.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1166-78 [10091803.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1875-80 [15536150.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):198-202 [16136581.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jun;28(6):362-8 [16794504.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):256-64 [17154164.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2008 Mar;52(1):9-16 [18235420.001]
  • [Cites] Neoplasma. 2008;55(2):96-100 [18237246.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):765-8 [17763463.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):820-6 [18422997.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3765-71 [12228196.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1209-18 [11728679.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):441-4 [12406083.001]
  • (PMID = 20494933.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2948094
  •  go-up   go-down


39. Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL: Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Eur J Nucl Med Mol Imaging; 2005 Oct;32(10):1225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
  • PURPOSE: The aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative radioimmunotherapy using 131I-rituximab in previously heavily treated patients with B-cell non-Hodgkin's lymphoma (B-NHL).
  • Four non-responders with bulky disease died 4.8+/-2.0 months after therapy.
  • Of two patients who received radioimmunotherapy as an additional treatment after salvage chemotherapy, one continues to be disease-free at 9 months and one relapsed at 5 months' follow-up.
  • Radioimmunotherapy was less efficient in patients with bulky disease and elevated LDH.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Pilot Projects. Radiation Injuries / etiology. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / therapeutic use. Severity of Illness Index. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):195-7 [9652253.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1363-72 [11877767.001]
  • [Cites] Clin Immunol. 2001 Jul;100(1):40-8 [11414744.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):58-65 [10561019.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] Nuklearmedizin. 2002 Apr;41(2):71-9 [11989301.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] J Nucl Med. 1990 Jan;31(1):84-9 [2295945.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1023-30 [8450856.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s [10541376.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Oct;29(10 ):1276-82 [12271407.001]
  • [Cites] J Clin Oncol. 1996 Jul;14 (7):1974-81 [8683227.001]
  • [Cites] J Nucl Med. 1998 Aug;39(8 Suppl):21S-27S [9708567.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3246-56 [9779698.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):341-53 [15172354.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):513-24 [14503945.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s [10541379.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] Cancer Immunol Immunother. 2003 May;52(5):281-96 [12700944.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):766-77 [10952488.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10 ):3270-8 [9779701.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1027-38 [2666588.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):10-7 [14962257.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Oncol. 1992 Nov;10 (11):1696-711 [1403053.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 15937686.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 131I-rituximab; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals
  •  go-up   go-down


40. Wang WH, Li YX, Song YW, Jin J, Liu YP, Wang SL, Zhou LQ, Liu XF, Yu ZH, Han JZ: [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease]. Zhonghua Zhong Liu Za Zhi; 2006 Mar;28(3):218-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
  • OBJECTIVE: To evaluate whether involved-field (IF) radiotherapy is equally effective and less toxic in comparison with extended-field (EF) radiotherapy for patients with early-stage Hodgkin's disease (HD) who received combined modality therapy.
  • METHODS: The data of 88 early-stage HD patients treated with combined modality therapy were retrospectively reviewed.
  • According to Ann Arbor classification, 12 patients (13.7%) had stage IA disease, 56 stage IIA (63.6%), and 20 IIB (22.7%).
  • CONCLUSION: Compared with extended-field radiotherapy, involved-field radiotherapy is equally effective and less toxic for patient with early-stage Hodgkin's disease treated with combined modality therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymphatic Irradiation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Leukopenia / etiology. Lymphatic Metastasis. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Retrospective Studies. Survival Rate. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875611.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


41. Olivares Camacho JL, Cabrera V, Cabrera JI: [Hodgkin's lymphoma with thoracic column metastasis. A case report]. Acta Ortop Mex; 2008 Jan-Feb;22(1):62-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's lymphoma with thoracic column metastasis. A case report].
  • [Transliterated title] Linfoma de Hodgkin con metástasis a columna torácica. Presentación de caso.
  • This 20 years old male patient with a history of Hodgkin's disease since 1996, stage II variety nodular sclerosis, was initially managed with radiotherapy and chemotherapy ending such treatment in January 1997, subsequently treated with interferon for one year, ending in January 1998, presented complete remission and was maintained in observation; in June 1999 started with thoracolumbar pain, weakness and diminished sensitivity on lower limbs, studies were conducted and diagnosed epidural tumor from levels T9 to T12, with important spinal cord compression; the patient was submitted to surgery and neurological recovery was complete.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / surgery. Spinal Neoplasms / secondary. Thoracic Vertebrae
  • [MeSH-minor] Adult. Humans. Male. Orthopedic Procedures / methods

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672756.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


42. Wang W, Gao L, Wang LL, Li MY, Li YY, Zhao W, Xu YY, Ding Y, Yu L: [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1204-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis].
  • This study was purposed to investigate the significance of using (FCM) flow cytometry for detection bone marrow involvement by lymphoma cells in untreated patients with B cell non-Hodgkin's lymphoma (B-NHL).
  • Even in patients with early stage, lymphoma cells still could be detected by FCM in involved bone marrow.
  • Evaluation whether the bone marrow has been involved by lymphoma cells should be recommend to every patient with B-NHL before chemotherapy and every disease stages.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129261.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Thirty-three patients received involved-field radiotherapy prior to stem cell transplantation directed at symptomatic and/or bulky sites; eight patients received involved-field radiotherapy after stem cell transplantation directed at sites of persistent disease.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Female. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Alm El-Din MA, Hughes KS, Finkelstein DM, Betts KA, Yock TI, Tarbell NJ, Aisenberg AC, Taghian AG: Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter.
  • PURPOSE: To evaluate the risk of breast cancer (BC) and the contributing risk factors in women after supradiaphragmatic irradiation (SDI) for Hodgkin's lymphoma (HL).
  • SUBJECTS AND METHODS: Medical records of 248 women 60 years of age or less who received SDI for stage I/II HL between 1964 and 2001 at Massachusetts General Hospital were retrospectively reviewed.
  • [MeSH-major] Breast Neoplasms / epidemiology. Hodgkin Disease / epidemiology. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / statistics & numerical data. Risk Assessment / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Comorbidity. Female. Humans. Incidence. Massachusetts / epidemiology. Middle Aged. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538497.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009337
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Rini JN, Núñez R, Nichols K, Tronco GG, Tomas MB, Hart D, Karayalcin G, Leonidas JC, Palestro CJ: Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol; 2005 Feb;35(2):169-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease.
  • Coincidence-detection 18F-FDG-PET (PET) and 67Ga whole-body and SPECT (Ga) were compared in children and young adults with newly diagnosed Hodgkin's disease (HD).
  • MATERIALS AND METHODS: Thirty patients with histologically confirmed HD underwent PET with attenuation correction 1 h after injection of 150-220 MBq 18F-FDG and whole-body and SPECT imaging 72 h after injection of 250-370 MBq 67Ga citrate.
  • Comparison was made with disease sites (established by biopsy or two or more of the following: physical examination, conventional imaging studies, radionuclide studies, and follow-up studies) and clinical stages.
  • RESULTS: PET detected 120/138 (87%) disease sites and Ga 109/138 (79%).
  • Accuracies were not significantly different for supradiaphragmatic disease.
  • PET was more accurate than Ga for detecting splenic (0.91 vs 0.61, P = 0.012), infradiaphragmatic (0.89 vs 0.75, P = 0.042), and all disease sites combined (0.95 vs 0.91, P = 0.039).
  • PET stage agreed with clinical stage in 79% of patients and Ga in 71%.
  • CONCLUSION: PET was superior to Ga for evaluating children and young adults with newly diagnosed HD.
  • [MeSH-major] Fluorodeoxyglucose F18. Gallium Radioisotopes. Hodgkin Disease / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. False Positive Reactions. Female. Humans. Image Interpretation, Computer-Assisted. Male. Neoplasm Staging. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Spleen / diagnostic imaging. Spleen / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2218-25 [8229137.001]
  • [Cites] Am J Med. 2002 Mar;112(4):262-8 [11893364.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Rofo. 1980 Jan;132(1):21-30 [6446494.001]
  • [Cites] Clin Nucl Med. 2002 Aug;27(8):572-7 [12170002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):93-9 [8270463.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jan;26(1):74-6 [14707721.001]
  • [Cites] Radiol Clin North Am. 2001 Sep;39(5):957-78 [11587064.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10 ):1564-78 [11083548.001]
  • [Cites] Radiology. 1985 Mar;154(3):753-7 [3969481.001]
  • [Cites] Radiology. 1997 Jun;203(3):795-800 [9169707.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):879-88 [11920454.001]
  • [Cites] J Am Geriatr Soc. 2000 Mar;48(3):315-7 [10733060.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Mar-Apr;20(2):174-6 [9544173.001]
  • [Cites] Nuklearmedizin. 1998;37(7):251-3 [9830616.001]
  • [Cites] Am J Med. 1983 Aug;75(2):327-31 [6881185.001]
  • [Cites] J Nucl Med. 2003 Jul;44(7):1072-4 [12843223.001]
  • [Cites] J Nucl Med. 2001 Apr;42(4):601-8 [11337549.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):990-4 [9189158.001]
  • [Cites] Oncol Rep. 2002 Mar-Apr;9(2):321-5 [11836600.001]
  • [Cites] Radiology. 2003 May;227(2):353-60 [12637679.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):343-8 [9074514.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Clin Lymphoma. 2000 Jun;1(1):67-74; discussion 75-6 [11707816.001]
  • [Cites] Pediatr Clin North Am. 2002 Oct;49(5):1027-42 [12430624.001]
  • (PMID = 15549284.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Oehler-Jänne C, Taverna C, Stanek N, Negretti L, Lütolf UM, Ciernik IF: Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. Hematol Oncol; 2008 Jun;26(2):82-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study.
  • The role of involved field radiation therapy (IF-RT) after high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for non-Hodgkin's lymphoma (NHL) has not been conclusively defined.
  • Fifteen patients treated with IF-RT after ASCT were compared with 15 patients without IF-RT, identical for histology, stage and treatment response to HDC/ASCT as well as comparable for international prognostic index (IPI) score, age and gender.
  • In most of the cases, local relapse was seen in patients with bulky disease.
  • Long-term toxicities observed after IF-RT were coronary artery disease, secondary malignancy unrelated to the RT-field, angina abdominalis, hypothyroidism and teeth decay.
  • Recurrence of NHL at sites of macroscopic disease remains common despite HDC.
  • IF-RT achieves excellent local regional control and consolidative IF-RT after ASCT seems indicated, particularly in patients with bulky disease.
  • In the absence of a prospective randomized trial and proven impact on survival rates, IF-RT can be recommended as an option post-ASCT to enhance local disease control.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Combined Modality Therapy. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Radiotherapy / methods. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085574.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, Kim DS, Shin SO, Cho HS, Bae SH, Ryoo HM: Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol; 2005 Jan;84(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-Hodgkin's lymphomas of the orbit and ocular adnexa (OOA), the majority of which are extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type (MALT lymphomas), are a rare disorder.
  • The aim of this study was to evaluate the clinical features and treatment outcomes and complications in patients with MALT lymphoma of OOA.
  • Thirty-seven patients with a histologically verified diagnosis of MALT lymphoma of OOA were included in this retrospective, observational case study.
  • Combination chemotherapy alone was employed in three patients with stage IIIA(E) or IVA(E).
  • Subgroup analysis of the patients with localized disease, who received radiotherapy as an initial treatment modality, revealed that 3-year OS rate and EFS rate were 100% and 93%, respectively.
  • All disease recurrences were documented histologically as MALT lymphoma.
  • Radiotherapy alone can produce excellent local control and survival in patients with localized MALT lymphoma of OOA.
  • [MeSH-major] Eye Neoplasms. Lymphoma, B-Cell, Marginal Zone
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Orbital Neoplasms / complications. Orbital Neoplasms / pathology. Orbital Neoplasms / therapy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15309523.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med; 2010 Aug 12;363(7):640-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
  • BACKGROUND: Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin's lymphoma with a favorable prognosis remains unclear.
  • METHODS: We randomly assigned 1370 patients with newly diagnosed early-stage Hodgkin's lymphoma with a favorable prognosis to one of four treatment groups: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of radiation therapy (group 1), four cycles of ABVD followed by 20 Gy of radiation therapy (group 2), two cycles of ABVD followed by 30 Gy of radiation therapy (group 3), or two cycles of ABVD followed by 20 Gy of radiation therapy (group 4).
  • CONCLUSIONS: In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Young Adult


49. Nogovà L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin's lymphoma.
  • Lymphocyte-predominant Hodgkin's lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • Treatment of LPHL patients using standard Hodgkin's lymphoma protocols leads to complete remission in more than 95% of patients.
  • Survival and freedom from treatment failure are substantially worse in advanced-stage patients than for early-stage patients.
  • In contrast, patients with early-stage LPHL without risk factors might be sufficiently treated with reduced-intensity programs having less severe adverse effects.
  • IF-RT seems to be emerging as a treatment of choice for patients with stage IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer, have adopted IF-RT as the treatment of choice for these patients.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Histiocytes / pathology. Humans. Lymphocytes / pathology. Neoplasm Staging. Patient Selection. Prognosis. Radiotherapy Dosage. Remission Induction. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Histopathology. 1990 Feb;16(2):157-65 [2323737.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):559-65 [8573534.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):99-106 [3791150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):377-83 [12416895.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7 [12972802.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1903-10 [14738141.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Feb;17(1):47-53 [15714929.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • (PMID = 20425333.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 25
  •  go-up   go-down


50. Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A, Ozkan M, Er O, Cetin M, Unal A: Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. Am J Hematol; 2006 May;81(5):307-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
  • However, there are limited studies regarding the effect of Fas expression on the course and prognosis of non-Hodgkin's lymphoma.
  • The aim of this study was to investigate the significance of immunohistochemical Fas expression on the prognosis of nodal diffuse large B-cell lymphoma.
  • A total of 63 patients with primary nodal diffuse large B-cell lymphoma diagnosed in the Erciyes University Department of Hematology between 1990 and 2003 were included in the study.
  • Clinical and laboratory parameters including Fas, bcl-2, and p53 positivity, age, sex, performance status, clinical stage, presence of B symptoms, bone marrow involvement, extranodal involvement, and lactic dehydrogenase levels were evaluated to compare overall survival.
  • Fas positivity, male gender, good performance status, clinical stage I-II, absence of B symptoms, normal lactic dehydrogenase value, and absence of bone marrow involvement were favorable prognostic factors for complete remission in statistical analysis.
  • Immunohistochemical Fas positivity was a favorable prognostic factor for complete remission and overall and progression-free survival in primary nodal diffuse large B-cell lymphoma.
  • [MeSH-major] Antigens, CD95 / analysis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • [CommentIn] Am J Hematol. 2007 Apr;82(4):331-2 [17019688.001]
  • (PMID = 16628716.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


51. Scott SM, Schlaff W: Laparoscopic medial oophoropexy prior to radiation therapy in an adolescent with Hodgkin's disease. J Pediatr Adolesc Gynecol; 2005 Oct;18(5):355-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic medial oophoropexy prior to radiation therapy in an adolescent with Hodgkin's disease.
  • BACKGROUND: Advances in radiation therapy have led to long term survival in young patients with Hodgkin's disease.
  • CASE: An adolescent female underwent a laparoscopic medial oophoropexy prior to radiation therapy for Stage IIIB Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Laparoscopy. Ligaments / surgery. Ovary / surgery. Primary Ovarian Insufficiency / prevention & control. Radiation Injuries / prevention & control
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202940.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most patients had bulky disease: three had a diameter >5 cm and eight a diameter >10 cm.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Registries. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


53. Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S: Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion; 2007 Dec;47(12):2207-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The successful mobilization and collection of hematopoietic stem cells are dependent on a number of clinical factors such as previous chemotherapy and disease stage.
  • This retrospective study included patients with diagnoses of acute myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and solid tumors.
  • Reinfused CD34+ cell dose of less than 12 x 10(6) and number of days stem cell collection to reach this minimum CD34+ cell dose did not independently affect the overall survival (OS) or disease-free survival (DFS).
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / analysis. Child. Child, Preschool. Combined Modality Therapy. Female. Granulocyte Colony-Stimulating Factor / pharmacology. Hodgkin Disease / metabolism. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / metabolism. Multiple Myeloma / therapy. Prognosis. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714420.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / P30 CA33572
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


54. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, Nihashi T, Nagai H: Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol; 2009 Apr 10;27(11):1906-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
  • PURPOSE: To systematically review the prognostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) for interim response assessment of patients with untreated advanced-stage Hodgkin's lymphoma (HL) or diffuse large B-cell lymphoma (DLBCL).
  • RESULTS: Thirteen studies involving 360 advanced-stage HL patients and 311 DLBCL patients met our inclusion criteria.
  • Advanced-stage HL studies included few unfavorable-risk patients.
  • FDG-PET had an overall sensitivity of 0.81 (95% CI, 0.72 to 0.89) and a specificity of 0.97 (95% CI, 0.94 to 0.99) for advanced-stage HL, and a sensitivity of 0.78 (95% CI, 0.64 to 0.87) and a specificity of 0.87 (95% CI, 0.75 to 0.93) for DLBCL.
  • CONCLUSION: For low- to intermediate-risk advanced-stage HL, FDG-PET performed after a few cycles of standard chemotherapy seems to be a reliable prognostic test to identify poor responders, warranting prospective studies to assess PET-based treatment strategies.
  • [MeSH-major] Hodgkin Disease / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Fluorodeoxyglucose F18. Humans. Predictive Value of Tests. Prognosis. Radiopharmaceuticals


55. Bai CM, Yang T, Xü Y, Zhang W, Liu XL, Zhu YL, Chen SC, Shen T: [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):142-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factors in primary intestinal non-Hodgkin's lymphoma.
  • METHODS: The clinical presentations, pathological features and therapeutic results of 32 primary intestinal non-Hodgkin's lymphoma were retrospectively analyzed.
  • Twenty-one patients (65.6%) were diagnosed as B-cell lymphoma, 15 (46.9%) were diffuse large B-cell lymphoma.
  • Ten patients (31.2%) were diagnosed as T-cell lymphoma and one (3.1%) as histiocytic lymphoma.
  • Based on Cox multivariate analysis, stage III - IV, B symptoms and T cell phenotype of the disease were the independent adverse prognostic factors (P < 0.05).
  • CONCLUSION: The clinical presentation of primary intestinal non-Hodgkin's lymphoma are not specific clinically.
  • Most of the histological types are diffuse large B-cell type lymphoma.
  • Complete resection combined with chemotherapy may be the best effective approach for treatment of this disease.
  • The prognosis of this disease are correlated with the stage, B symptoms and T cell phenotype.
  • [MeSH-major] Intestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750023.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Niitsu N, Nakamine H, Okamoto M, Tamaru JI, Hirano M: A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma. Ann Oncol; 2008 Nov;19(11):1941-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma.
  • BACKGROUND: We carried out immunohistochemistry to examine the expression of nm23-H1 in Hodgkin and Reed-Sternberg cells in patients with classical Hodgkin's lymphoma (CHL).
  • Univariate analysis showed that stage IV, poor performance status, low hemoglobin level, low serum albumin level, age of 45 years or older, TIA-1-positive status, and nm23-H1-positive status were associated with significantly shorter progression-free survival.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647967.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


57. Gisselbrecht C, Mounier N, André M, Casanovas O, Reman O, Sebban C, Divine M, Brice P, Briere J, Hennequin C, Fermé C: How to define intermediate stage in Hodgkin's lymphoma? Eur J Haematol Suppl; 2005 Jul;(66):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to define intermediate stage in Hodgkin's lymphoma?
  • BACKGROUND: Intermediate or unfavourable stage Hodgkin's lymphoma (HL) definition relies upon at least three different scoring systems defined by cooperative groups (EORTC, GHSG and Canadian-ECOG).
  • PATIENTS AND METHODS: We studied a population of 1156 patients with localized stage HL treated prospectively within GELA centres in H8 (518 patients) and H9 (638 patients) protocols.
  • Median age: 30 yr, 18%, Female 50%; stage I: 25%; stage II: 75%.
  • This new score should be validated in other prospective trials, as it will simplify the Hodgkin prognostic scoring systems for localized and advanced stages.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy. Neoplasm Staging
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007878.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Denmark
  •  go-up   go-down


58. Harrington KJ, Michalaki VJ, Vini L, Nutting CM, Syrigos KN, A'hern R, Harmer CL: Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience. Br J Radiol; 2005 May;78(929):405-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience.
  • A retrospective review was conducted of patients treated for thyroid non-Hodgkin's lymphoma (TNHL) at the Royal Marsden Hospital between 1936 and 1996 to determine the effect of radiotherapy (RT) on outcome.
  • EFRT alone for Stage I, but not for Stage II disease, yielded acceptable rates of local control and disease free survival with doses of at least 40 Gy.
  • These historical data strongly support the addition of combination chemotherapy to the treatment regimen in all patients with Stage II disease.
  • Indeed, in recent years this has become the standard of care for all cases of thyroid lymphoma unless the histology is of marginal zone type (mucosa associated lymphoma tissue (MALT) lymphoma).
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Thyroid Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. London. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15845932.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Connors JM: State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol; 2005 Sep 10;23(26):6400-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State-of-the-art therapeutics: Hodgkin's lymphoma.
  • Presently Hodgkin's lymphoma can be cured in at least 80% of patients.
  • The major challenge to the clinician in 2005 is how to cure the disease while inducing the least irreversible toxicity.
  • This review focuses on clinical trials and institutional experiences to identify the best choice of treatment, individualized to the stage of the lymphoma permitting minimization of late toxicity such as infertility, premature menopause, cardiac disease, and most importantly, risk of second neoplasms.
  • More than 90% of patients with limited Hodgkin's lymphoma can be cured with either short-course chemotherapy alone or even briefer chemotherapy followed by involved-field radiation.
  • Accumulating evidence suggests that chemotherapy alone is suitable for the large majority of patients with limited disease.
  • For the 80% of patients with advanced disease but without a large number of adverse prognostic factors, standard multi-agent chemotherapy with the well-established ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) provides the best balance of effectiveness and minimization of toxicity.
  • In 2005 it is insufficient to focus solely on cure of Hodgkin's lymphoma.
  • Fortunately, brief chemotherapy alone or with radiation for patients with limited disease and standard ABVD chemotherapy for patients with advanced disease offer the appropriate balance of these two requirements.
  • Patients with advanced disease plus multiple indicators of a poor prognosis and patients with disease that persists despite optimized primary treatment require specially intensified treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Severity of Illness Index. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155026.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 72
  •  go-up   go-down


60. Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ: Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc; 2010 Apr;42(3):843-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In case 1, a 38-year-old male HBV carrier with a neck mass was hisopathologically diagnosed as Hodgkin's lymphoma.
  • Soon, he developed grade IV hepatic encephalopathy with a total bilirubin level of 50.56 mg/dL and a model for End-Stage Liver Disease score of 40.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Carrier State. Disease-Free Survival. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Living Donors. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20430187.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


61. Visco C, Nadali G, Vassilakopoulos TP, Bonfante V, Viviani S, Gianni AM, Federico M, Luminari S, Peethambaram P, Witzig TE, Pangalis G, Cabanillas F, Medeiros LJ, Sarris AH, Pizzolo G: Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol; 2006 Nov;77(5):387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
  • OBJECTIVES: To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens.
  • With multivariate analysis, sCD30, Ann Arbor stage, and lactic acid dehydrogenase were significant independent factors in terms of FFS.
  • [MeSH-major] Antigens, CD30 / blood. Biomarkers, Tumor / blood. Hodgkin Disease / blood. Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / methods. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Failure. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879607.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


62. Baijal G, Vadiraja BM, Fernandes DJ, Vidyasagar MS: Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly. J Cancer Res Ther; 2009 Apr-Jun;5(2):140-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly.
  • Non-Hodgkin's lymphoma (NHL) of the uterine cervix is exceedingly rare.
  • The management of the disease is not standardized.
  • She was diagnosed as stage IE after staging work-up, and managed with three courses of rituximab, cyclophosphamide, vincristine, adriamycin, and prednisolone followed by external beam radiotherapy (46 Gy in 23 fractions) by 3D conformal technique.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542675.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


63. Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO, Prosnitz LR: Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol; 2006 Feb 1;24(4):605-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
  • PURPOSE: The treatment of early-stage Hodgkin's disease (HD) has evolved from radiotherapy alone (RT) to combined-modality therapy (CMT) because of concerns about late adverse effects from high-dose subtotal nodal irradiation (STNI).
  • This retrospective study compares the long-term results of STNI with CMT using modestly reduced RT dose in the treatment of early-stage HD.
  • PATIENTS AND METHODS: Between 1982 and 2002, 111 patients with stage IA and IIA HD were treated definitively with RT (mean dose, 37.9 Gy); 70 patients were treated with CMT with low-dose involved-field radiotherapy (LDIFRT; mean dose, 25.5 Gy).
  • CONCLUSION: In this retrospective review, CMT with LDIFRT was effective in curing early-stage HD and was not associated with an increase in second malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Coronary Disease / prevention & control. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Chemotherapy, Adjuvant / adverse effects. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Lymph Nodes / radiation effects. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Feb 1;24(4):544-8 [16446326.001]
  • (PMID = 16446333.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Clavel J, Steliarova-Foucher E, Berger C, Danon S, Valerianova Z: Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project. Eur J Cancer; 2006 Sep;42(13):2037-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project.
  • This paper reports the geographical patterns and time trends of incidence and survival of Hodgkin's disease (HD) in children and adolescents in Europe over the period 1978-1997.
  • Data on 4230 HD cases were gathered from 62 paediatric or general cancer registries in 19 European countries by the Automated Cancer Information System (ACCIS).
  • In future, detailed documentation of cases in the cancer registries with respect to standardised diagnostic subtypes, stage of extension, and treatments, will help to refine interpretation of international and temporal variations in incidence and survival.
  • [MeSH-major] Databases, Factual / statistics & numerical data. Hodgkin Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Europe / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Registries / statistics & numerical data. Residence Characteristics. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919769.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Sotnikov VM, Pan'shin GA, Datsenko PV, Ivashin AV, Smol'tsova NN: [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of adjuvant radiotherapy in the complex treatment of stage III-IV aggressive non-Hodgkin's lymphoma].
  • Immediate and end results of chemoradiotherapy of 225 patients (average age--43 years) with primary aggressive non-Hodgkin's lymphomas stage III-IV were evaluated.
  • Stage 1 of treatment included 4-8 cycles of chemotherapy (ACOP and other standard protocols); stage 2--irradiation of residual foci with 20-50 Gy, or 20-36 Gy for originally extensive and extralymphatic foci when in full remission.
  • The disease is specific, so relapse-free survival in cases of generalized primary aggressive lymphoma in full remission remained unchanged too whatever the stage at which full remission emerged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947367.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


66. Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM: Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol; 2010 Jan 1;28(1):136-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
  • PURPOSE The optimal treatment for early-stage, lymphocyte-predominant Hodgkin's lymphoma (LPHL) is not well defined.
  • PATIENTS AND METHODS The study population includes 113 patients with stage I or II LPHL treated between 1970 and 2005.
  • Ten-year progression-free survival (PFS) rates were 85% (stage I) and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II, respectively.
  • In contrast, six of seven patients who received chemotherapy alone without RT developed early disease progression and required salvage treatment.
  • Multivariable analysis adjusting for extent of RT, clinical stage, sex, and use of chemotherapy confirmed that the extent of RT was not significantly associated with PFS (P = .67) or OS (P = .99).
  • CONCLUSION RT alone leads to sustained disease control and high long-term survival rates in patients with early-stage LPHL.
  • This study supports the use of limited-field RT alone to treat this disease.
  • [MeSH-major] Hodgkin Disease / mortality. Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Failure

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933914.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Kanaev SV, Girshovich MM, Golovanov SG, Gershanovich ML: [Can extended induction chemoradiotherapy be effective in the combined treatment of stage IIIB Hodgkin's disease ?]. Vopr Onkol; 2009;55(5):562-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can extended induction chemoradiotherapy be effective in the combined treatment of stage IIIB Hodgkin's disease ?].
  • The paper evaluates the results of chemoradiaton (2-4 cycles of preliminary treatment to suppress intoxication symptoms plus total, or subtotal exposure of the lymph nodes to tumor-killing doses in cases of intact iliac inguinal nodes) in 89 patients with Hodgkin's disease stage IIIB.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods. Remission Induction / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020650.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


68. Krawczuk-Rybak M, Solarz E, Gadomski J, Matysiak M, Wołczyński S: [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):623-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood].
  • AIM: To investigate testicular function (spermato- and steroidogenesis) in adolescents and young men cured of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • Patients with NHL and HL in clinical stage I and IIb, presented normal values of all analyzed parameters.
  • 2. The treatment for HL in IIb, IIIb, IV clinical stage with increasing number of therapeutic protocols, especially together with radiotherapy, led to gonadal dysfunction (increase of FSH, decrease of inhibin B values).
  • Treatment for HL of higher clinical stage leads to gonadal dysfunction, especially of spermatogenesis.
  • [MeSH-major] Combined Modality Therapy / adverse effects. Gonadotropins, Pituitary / blood. Hodgkin Disease / therapy. Infertility, Male / etiology. Lymphoma, Non-Hodgkin / therapy. Spermatogenesis / drug effects. Spermatogenesis / radiation effects
  • [MeSH-minor] Adolescent. Adult. Child. Enzyme-Linked Immunosorbent Assay. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Male. Neoplasm Staging. Testicular Diseases / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317893.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


69. Laatiri MA, Elloumi M, Ali ZB, Ben Othmen T, Msadek F, Toumi N, Bouaouina N, Daoud J, Maalej M, Ghannem H, Meddeb B: [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients]. Bull Cancer; 2010 Apr;97(4):409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
  • From January 1997 to December 2005, 337 patients with aggressive non Hodgkin's lymphoma were treated with one of the two successive multicentric non randomized protocols established in Tunisia.
  • Most patients had diffuse large cell lymphoma with B phenotype in 86% and T in 14%.
  • Advanced disease (III or IV stage) was noted in 59% of cases and 10% had a tumoral mass greater than 10 cm.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Karnofsky Performance Status. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prospective Studies. Remission Induction / methods. Rituximab. Stem Cell Transplantation. Survival Analysis. Tunisia. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374978.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; CEOP protocol 2; CHOEP protocol; CHOP protocol
  •  go-up   go-down


70. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J: Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm; 2007 May;13(4):337-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To (1) describe the use of pegfilgrastim and filgrastim in oncology practices throughout the United States and (2) compare their effectiveness in actual practice as measured by the outcome of febrile neutropenia in patients who received chemotherapy regimens administered every 3 to 4 weeks for breast, lung, ovarian, colon cancer, or lymphoma and who received a CSF prior to developing FN.
  • METHODS: Data were retrospectively obtained from the medical records of a cohort of adult patients aged 18 years or older treated in 99 community oncology practices in the United States in 2001 and 2003.
  • Eligible patients were treated with chemotherapy every 3 to 4 weeks for breast, lung, ovarian, colon cancer, or lymphoma and were users of filgrastim in 2001 (prior to the U.S.
  • Patients who received pegfilgrastim were more likely to have at least 1 myelosuppressive drug (74.8%) in the regimen compared with patients who received filgrastim in 2003 (70.0%, P = 0.013), but a greater proportion of filgrastim patients in 2003 (19.4%) had advanced-stage disease compared with pegfilgrastim patients (14.8%, P = 0.005).
  • More patients who received filgrastim in 2003 (36.2%) had a cancer other than breast cancer or non-Hodgkin's lymphoma compared with those who received pegfilgrastim (29.5%, P = 0.001).

  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. Filgrastim .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506600.001).
  • [ISSN] 1083-4087
  • [Journal-full-title] Journal of managed care pharmacy : JMCP
  • [ISO-abbreviation] J Manag Care Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


71. Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A: [Our experiences in treating patients with Hodgkin disease in the last decade]. Orv Hetil; 2007 Apr 15;148(15):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Our experiences in treating patients with Hodgkin disease in the last decade].
  • [Transliterated title] Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben.
  • INTRODUCTION: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred.
  • AIM: To summarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004.
  • RESULTS: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%).
  • 41.1% of the patients was at early stage, 15.7% had the worst prognosis, while 28.8% had bulky tumor.
  • During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons.
  • CONCLUSION: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hungary. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416575.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol; MOPP protocol
  •  go-up   go-down


72. Park YH, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH: Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Ann Hematol; 2006 May;85(5):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
  • Burkitt lymphoma/leukemia (BL) is a highly aggressive non-Hodgkin's lymphoma (NHL) often presenting in extranodal sites or as an acute leukemia.
  • Because of the shared molecular and genetic features, the World Health Organization classification of lymphoid diseases recognizes the lymphomatous and leukemic phases of BL as a single entity: a mature B cell neoplasm, subtype Burkitt lymphoma/Burkitt cell leukemia.
  • Stage 1 was found in five patients, stage 2 in five patients, and stage 4 in 11 patients.
  • Both the 2-year disease-free and overall survival rates were 55%.
  • These data show that a high proportion of patients with gastric BL have a localized disease that is limited to stage 1 and 2, and that these localized BLs have outstanding outcomes.
  • [MeSH-major] Burkitt Lymphoma / mortality. Stomach Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518604.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Van Hauwaert V, Meers S, Verhoef G, Tousseyn T, Sagaert X, Vermeire S, Rutgeerts P, Van Assche G: Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis; 2010 Dec;4(6):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis.
  • A 20-year old man with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) was diagnosed with a rectal non-Hodgkin's lymphoma (NHL) at surveillance endoscopy while being in remission on infliximab therapy.
  • Further staging identified a diffuse large B-cell NHL, EBV negative restricted to the rectal submucosa (stage IA).
  • However, IBD patients treated with purine analogues and with anti-TNF are at risk of NHL, especially hepatosplenic T-cell lymphoma.
  • The management of this particular young patient is further complicated by the possibility of a future colectomy due to intractable disease which compromises the use of radiotherapy for this localized disease.

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [ErratumIn] J Crohns Colitis. 2011 Feb;5(1):79. Tousseyn, Thomas [added]; Sagaert, Xavier [added]
  • (PMID = 21122582.001).
  • [ISSN] 1876-4479
  • [Journal-full-title] Journal of Crohn's & colitis
  • [ISO-abbreviation] J Crohns Colitis
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


74. Chalastras T, Elefteriadou A, Giotakis J, Soulandikas K, Korres S, Ferekidis E, Kandiloros D: Non-Hodgkin's lymphoma of nasal cavity and paranasal sinuses. A clinicopathological and immunohistochemical study. Acta Otorhinolaryngol Ital; 2007 Feb;27(1):6-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of nasal cavity and paranasal sinuses. A clinicopathological and immunohistochemical study.
  • Aim of this study was to investigate the clinical characteristics, management and prognosis of non-Hodgkin lymphomas of the nasal cavity and paranasal sinuses.
  • Overall 12 patients with non-Hodgkin malignant lymphoma, at our Institute, were studied over an eight-year period from 1997 to 2005.
  • Treatment administered: only radiotherapy (stage IEA) or in combination with chemotherapy (IIE-IVE).
  • Of these patients, 5 died from the disease, 4 survived without disease, 2 survived with the disease, and one died of non-related causes.
  • Non-Hodgkin's lymphomas are relatively rare.
  • Early diagnosis, based mainly on tissue biopsy and computerised tomography, is essential in the management of non-Hodgkin lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / radiography. Paranasal Sinus Neoplasms / immunology. Paranasal Sinus Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Cavity. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1213-6 [10923086.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Apr;108(4):411-9 [10214792.001]
  • [Cites] Auris Nasus Larynx. 2001 Jan;28(1):55-60 [11137364.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Mar;97(3):328-31 [15024355.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):768-76 [4016670.001]
  • [Cites] Pathology. 1986 Oct;18(4):419-25 [3493470.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):636-42 [2661407.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):268-79 [1996731.001]
  • [Cites] CA Cancer J Clin. 1993 Jan-Feb;43(1):7-26 [8422609.001]
  • [Cites] Blood. 1993 May 15;81(10):2688-95 [8387835.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Apr;103(4 Pt 1):294-300 [8154771.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1281-91 [7882278.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Laryngoscope. 2000 Sep;110(9):1489-92 [10983948.001]
  • (PMID = 17601204.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2640014
  •  go-up   go-down


75. Das P, Ng AK, Stevenson MA, Mauch PM: Clinical course of thoracic cancers in Hodgkin's disease survivors. Ann Oncol; 2005 May;16(5):793-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical course of thoracic cancers in Hodgkin's disease survivors.
  • BACKGROUND: Hodgkin's disease survivors have a high risk of subsequently developing thoracic cancers.
  • Our goal was to evaluate the prognosis and treatment outcomes of thoracic cancers after Hodgkin's disease.
  • PATIENTS AND METHODS: Thirty-three patients treated for Hodgkin's disease at Harvard-affiliated hospitals subsequently developed small-cell lung carcinoma, non-small-cell lung carcinoma (NSCLC) or mesothelioma.
  • Information was obtained from medical records about the initial treatment for Hodgkin's disease, any salvage therapy, smoking history, and the stage, histology, treatment and survival for thoracic cancers.
  • The median time between diagnosis of Hodgkin's disease and diagnosis of thoracic cancer was 17.3 years (range 1.2-27.9 years).
  • Among patients with NSCLC and a known stage, 85% presented with stage III or stage IV disease.
  • CONCLUSIONS: Most patients with thoracic cancers after Hodgkin's disease have a history of exposure to risk factors and present at an advanced stage.
  • Patients with thoracic cancers after Hodgkin's disease have a poor survival.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802277.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Niibe Y, Hayakawa K, Kitano M, Ishiyama H, Nakayama M, Yao K, Okamoto M: Successful treatment of concurrent chemoradiotherapy for stage I nasal NK/T cell lymphoma: a report of two cases. Anticancer Res; 2005 Nov-Dec;25(6C):4403-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of concurrent chemoradiotherapy for stage I nasal NK/T cell lymphoma: a report of two cases.
  • Nasal natural killer/T cell (NK/T cell) lymphoma is a rare subtype of lymphomas, being a subtype of non-Hodgkin's lymphoma with a much worse prognosis than other subtypes.
  • One reason for this worse prognosis is that nasal NK/T cell lymphoma is resistant to standard sequential chemoradiotherapy.
  • Thus, we adopted concurrent chemoradiotherapy using a CHOP-like regimen for treating stage I nasal NK/T cell lymphoma.
  • These results suggest that concurrent chemoradiotherapy using a CHOP-like regimen for stage I nasal NK/T cell lymphoma provided sufficient dose intensity and may be a useful treatment option.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Killer Cells, Natural / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334116.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


77. Erkurt MA, Aydogdu I, Kuku I, Kaya E, Basaran Y: Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas: 10 years of experience from a single center in eastern Anatolia. Med Princ Pract; 2009;18(5):399-406
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas: 10 years of experience from a single center in eastern Anatolia.
  • OBJECTIVE: The objective of this retrospective study was to report the clinicopathological data and the treatment outcomes in patients with primary gastrointestinal non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: We carried out a retrospective analysis of 41 patients (22 females, 18 males, median age 58 and range 18-90 years) who presented to our department with histopathological diagnosis of primary gastrointestinal non-Hodgkin's lymphoma between 1995 and 2004.
  • The 3-year overall survival rate was better in patients with early-stage disease (stages I and II(1)) who were treated with surgery plus chemotherapy and/or radiation therapy than in those treated with chemotherapy alone (91.6 vs. 50%, p < 0.05).
  • The disease had a significant impact on both the progression-free survival and overall survival rates.
  • CONCLUSION: Our data showed that surgical resection prior to postoperative chemotherapy was a better option for patients with early-stage disease with better patient survival.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19648764.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


78. Fu XH, Wang SS, Huang Y, Xiao J, Zhai LZ, Xia ZJ, Huang HQ, Sun XF, Lin TY: [Prognostic significance of CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's Lymphoma]. Ai Zheng; 2008 Nov;27(11):1197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's Lymphoma].
  • BACKGROUND & OBJECTIVE: Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's Lymphoma (CHL) express B-cell marker CD20 with a reported frequency of 5%-58%.
  • Cox multivariate analysis showed that age and stage were independent prognostic factors for FFS and OS.
  • [MeSH-major] Antigens, CD20 / metabolism. Hodgkin Disease / immunology. Reed-Sternberg Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antigens, CD15 / metabolism. Antigens, CD30 / metabolism. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000453.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20; 0 / Antigens, CD30
  •  go-up   go-down


79. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol; 2006 May;17 Suppl 4:iv18-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
  • BACKGROUND: The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor.
  • RESULTS: Fourteen patients (median age 63 years, range 37-78 years) with relapsed (n = 9) or primary progressive (n = 5) aggressive (diffuse large cell, mantle cell, follicular G3), advanced (stage IV 71%), poor risk (IPI 3-5 50%) NHL were accrued in this pilot study.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702180.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


80. Guo HY, Zhao XM, Cao JN, Hu XC, Yin JL, Hong XN, Li J: [Prognosis of primary non-Hodgkin's lymphoma of the breast]. Zhonghua Zhong Liu Za Zhi; 2008 Mar;30(3):200-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of primary non-Hodgkin's lymphoma of the breast].
  • OBJECTIVE: To analyze the clinical characteristics and prognosis of primary non-Hodgkin's lymphoma of the breast (PNHLB).
  • RESULTS: Of these 45 patients, 37 patients had diffuse large B cell lymphoma (DLBCL), patients with T cell or mucosa-associated lymphoid tissue (MALT) lymphoma were 4, respectively.
  • The results of Cox regression model analysis showed that international prognostic index score (IPI) (RR = 5.682, P = 0.002) and Ann Arbor stage (RR = 1.836, P = 0.040) were negative independent prognostic factors for OS.
  • IPI and Ann Arbor stage are two independent prognostic factors for survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms, Male / drug therapy. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiotherapy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756936.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


81. Lorusso D, Ferrandina G, Pagano L, Gagliardi ML, Scambia G: Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery. Oncology; 2007;72(3-4):261-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery.
  • BACKGROUND: Primary non-Hodgkin's lymphoma involving the uterine cervix is extremely rare with a frequency of 0.008% of all cervical tumors.
  • No standard treatment has been defined for this disease.
  • CASE: A 29-year-old Caucasian woman with primary non-Hodgkin stage IE lymphoma of the uterine cervix was treated with neoadjuvant chemotherapy and conservative surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Neoadjuvant Therapy. Prednisone / administration & dosage. Pregnancy. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18185021.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


82. Fridman MV, Demidchik IuE, Gedrevich ZE: [Synchronous polyneoplasia of the thyroid gland: problems of diagnosis and therapy]. Vopr Onkol; 2006;52(3):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Still another patient had a combination of Hodgkin's disease (nodular sclerosis, cellular stage) and papillary microcarcinoma dicceminated to lymph nodes.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191704.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


83. Gao Y, Huang HQ, Lin XB, Cai QQ, Pan ZH, Wang BF, Bu Q: [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma]. Ai Zheng; 2007 Aug;26(8):909-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory T-cell non-Hodgkin's lymphoma (T-NHL) is poor.
  • Multivariate analysis showed that serum lactate dehydrogenase (LDH) level (P=0.010), second-line Ann Arbor stage (P=0.009), second-line IPI score (P=0.015), autologous stem cell transplantation (P=0.026), performance status (P=0.002), and IMVP-16 regimen (P=0.026) were independent prognostic factors of relapsed or refractory T-NHL.
  • The prognosis of this disease is poor and the addition of intensive treatments, such as stem cell transplantation, should be considered when alleviated after chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697558.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


84. Rodríguez-Vigil B, Gómez-León N, Pinilla I, Hernández-Maraver D, Coya J, Martín-Curto L, Madero R: PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med; 2006 Oct;47(10):1643-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
  • This study prospectively compares the agreement between contrast-enhanced full-dose PET/CT and unenhanced low-dose PET/CT in lesion detection and initial staging of Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS: Forty-seven biopsy-proven lymphoma patients underwent a 18F-FDG PET/CT study that included unenhanced low-dose CT and enhanced full-dose CT for initial staging.
  • Lesion detection, number of sites affected in each anatomic region, and disease stage were assessed.
  • Agreement between the 2 types of PET/CT was almost perfect for disease stage (kappa = 0.92; P < 0.001).
  • CONCLUSION: Our study showed a good correlation between unenhanced low-dose PET/CT and contrast-enhanced full-dose PET/CT for lymph node and extranodal disease in lymphomas, suggesting that unenhanced low-dose PET/CT might suffice in most patients as the only imaging technique for the initial staging of lymphomas, reserving diagnostic CT for selected cases.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Prospective Studies. Radiation Dosage. Radiography, Abdominal. Sclerosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17015900.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Wang SA, Rahemtullah A, Faquin WC, Roepke J, Harris NL, Hasserjian RP: Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature. Mod Pathol; 2005 Dec;18(12):1577-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature.
  • Hodgkin's lymphoma rarely involves the thyroid gland.
  • We report the clinical and pathologic features of five cases of Hodgkin's lymphoma that presented as thyroid lesions.
  • One patient had a remote history of Hodgkin's lymphoma.
  • Thyroid fine-needle aspiration was performed before thyroidectomy in all cases; three of these cases contained some atypical cells, raising the possibility of Hodgkin's lymphoma.
  • Histologically, all cases were classical Hodgkin's lymphoma, nodular sclerosis subtype.
  • The four patients with primary thyroid lymphoma had Stage IIE disease.
  • A review of the English literature between 1962 and 2005 revealed 16 cases of thyroid Hodgkin's lymphoma, with a female preponderance and generally favorable outcome similar to the cases in our series.
  • Hodgkin's lymphoma of the thyroid is rare and can mimic a primary thyroid epithelial tumor or thyroiditis clinically.
  • Hodgkin's lymphoma should be considered in the differential diagnosis of thyroid neoplasms.
  • [MeSH-major] Hodgkin Disease / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Chronic Disease. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hypothyroidism. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Sclerosis / pathology. Thyroidectomy. Thyroiditis. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258502.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, Martini M, Larocca LM, Voso MT, Leone G: Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol; 2009 Aug;20(8):1408-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkin's lymphoma (HL), 63 with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkin's lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene.
  • Increased levels of plasma DNA were associated with advanced stage disease, presence of B-symptoms, elevated lactate dehydrogenase levels, and age >60 years (P = 0.009; <0.0001; <0.0001; 0.04, respectively).
  • CONCLUSION: Quantification of circulating DNA by real-time PCR at diagnosis can identify patients with elevated levels that are associated with disease characteristics indicating aggressive disease and poor prognosis.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465421.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / beta-Globins
  •  go-up   go-down


87. Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A, Intergruppo Italiano Linfomi (IIL): ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol; 2008 Apr;19(4):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
  • BACKGROUND: In 1997, the Intergruppo Italiano Linfomi started a randomized trial to evaluate, in unfavorable stage IA and IIA Hodgkin's lymphoma (HL) patients, the efficacy and toxicity of the low toxic epirubicin, vinblastine and etoposide (EVE) regimen followed by involved field radiotherapy in comparison to the gold standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimen followed by the same radiotherapy program.
  • PATIENTS AND METHODS: Patients should be younger than 65 years with unfavorable stage IA and IIA HL (i.e. stage IA or IIA with bulky disease and/or subdiaphragmatic disease, erythrocyte sedimentation rate higher than 40, extranodal (E) involvement, hilar involvement and more than three involved lymph node areas).
  • CONCLUSIONS: In unfavorable stage IA and IIA HL patients, no differences were observed between ABVD and EVE arms in terms of CR rate and OS.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180244.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


88. Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB: Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol; 2005 Jan 20;23(3):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.
  • PURPOSE: The Pediatric Oncology Group adopted a histology-based approach to non-Hodgkin's lymphoma and treated patients with advanced large-cell lymphoma on a separate protocol (doxorubicin, vincristine, prednisone, 6-mercaptopurin, and methotrexate; APO regimen).
  • PATIENTS AND METHODS: From December 1994 to April 2000, we enrolled 180 eligible pediatric patients with stage III/IV large-cell lymphoma (LCL); 90 patients were randomly assigned to the intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC) arm, 85 patients to the APO arm, and five patients directly to the APO arm by study design due to CNS involvement.
  • The 4-year EFS and OS were 71.8% (SE, 6.1%) and 88.1% (SE, 4.4%), respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) and 70.3% (SE, 9.0%), respectively, for patients with diffuse large B-cell lymphoma.
  • Only 11 patients required radiation (due to unresponsive bulky disease or CNS involvement).
  • CONCLUSION: The efficacy of incorporating IDM/HiDAC in the treatment plan of pediatric and adolescent patients with advanced-stage LCL was inconclusive as to its effect on EFS, regardless of the lymphoma phenotype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Staging
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Age Factors. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Infant. Infusions, Intravenous. Injections, Spinal. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659500.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; APO combination
  •  go-up   go-down


89. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI, Southwest Oncology Group: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol; 2006 Sep 1;24(25):4143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
  • PURPOSE: Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial.
  • PATIENTS AND METHODS: From 1999 to 2000, the Southwest Oncology Group (SWOG) conducted a phase II trial (S9911) to test a novel new regimen consisting of six cycles of CHOP chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I-131 tositumomab in 90 eligible patients with previously untreated, advanced-stage FL.
  • An analysis according to the Follicular Lymphoma International Prognostic Index showed that 21% of patients had high-risk features, 44% had intermediate-risk features, and 34% had low-risk features.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prednisone / administration & dosage. Radioimmunotherapy / methods. Survival Analysis. Treatment Outcome. United States. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):915-6; author reply 916-7 [17327620.001]
  • (PMID = 16896003.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58348; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / iodine-131 anti-B1 antibody; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


90. Hacıhanefioğlu A, Tarkun P, Gonullu E, Vardar O: Lymphomas of Waldeyer's ring: Clinical features, management and prognosis of eleven adult patients. Turk J Haematol; 2008 Jun 5;25(2):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomas of Waldeyer's ring: Clinical features, management and prognosis of eleven adult patients.
  • Lymphoma is the second most common neoplasm of the head and neck after squamous carcinoma.
  • The majority of lym¬phomas involving the head and neck are non-hodgkin's lymphomas.
  • Hodgkin's lymphoma is rare in Waldeyer's ring.
  • Between 1999 and 2006, the medical records and pathology data of all newly diagnosed, previously untreated adult patients with Waldeyer's ring lymphomas were retrospectively reviewed.
  • Approximately one month after the end of the scheduled initial management, patients were restaged for evidence of residual disease with physical examination, laboratory profiles and relevant radiologic studies.
  • Complete remission was achieved in 6 patients and partial remission in 3 patients; 1 patient did not achieve remission and 1 patient with anaplastic large cell lymphoma died.
  • The progression of patients with lymphoma is closely associated with the diagnosis, stage and histologic grade of the disease.
  • This series characterized the clinicopathologic features and outcomes of adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264443.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


91. Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles C, Kew A, Nelson M, Kanfer E: A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease. AIDS; 2008 Feb 19;22(4):539-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease.
  • A 44-year-old man with relapsed HIV-associated stage IV nodular sclerosing Hodgkin's disease underwent high-dose therapy with autologous stem cell transplantation.
  • Autologous stem cell transplantation is safe in HIV patients and can achieve long-term durable remissions in Hodgkin's disease.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Humans. Lomustine / administration & dosage. Male. Remission Induction / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301069.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


92. Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG: Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplant; 2010 Feb;45(2):303-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure.
  • Patients with diffuse large B-cell lymphoma (DLBCL) who do not achieve a complete response to front-line combination chemotherapy are often offered high-dose therapy and autologous hematopoietic cell transplantation (AHCT).
  • By univariate analyses, the following characteristics did not significantly impact OS: disease stage at diagnosis, age-adjusted IPI (International Prognostic Index) score, age > or =40 years, earlier radiotherapy and the use of FTBI in the conditioning regimen.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Aug 1;96(3):864-9 [10910898.001]
  • [Cites] Br J Haematol. 2008 Sep;142(5):786-92 [18564354.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2399-404 [11001890.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(5A):555-62 [11071261.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):406-13 [11208832.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):229-35 [11841421.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2344-52 [11981006.001]
  • [Cites] Blood. 2003 Jul 15;102(2):749-55 [12663455.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1504-9 [15367411.001]
  • [Cites] J Clin Oncol. 1988 Jul;6(7):1118-24 [3292712.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):423-31 [1999711.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1949-54 [1453209.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):214-9 [8558200.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):534-42 [8636768.001]
  • [Cites] Ann Oncol. 1996 Dec;7(10):1043-9 [9037363.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):711-7 [15581541.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4652-61 [15837965.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):631-7 [10997975.001]
  • (PMID = 19597427.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-18; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-18; United States / NCI NIH HHS / CA / P01-CA 49605
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ NIHMS205199; NLM/ PMC2886804
  •  go-up   go-down


93. Ma LF, Fan W: [18F-FDG uptake of lymphoma lesions of various histological subtypes]. Ai Zheng; 2009 Apr;28(4):425-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F-FDG uptake of lymphoma lesions of various histological subtypes].
  • BACKGROUND AND OBJECTIVE: Malignant lymphoma has high 2-fluorine-18-fluoro-2-deoxy-D-glucose (18F-FDG) uptake.
  • This study was to analyze 18F-FDG uptake of lymphoma lesions of various histological subtypes.
  • METHODS: FDG PET/CT images of 102 naive lymphoma patients were analyzed.
  • The mean T/MB value of the patients with the same subtype of lymphoma was calculated.
  • The differences in T/MB value between Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) patients, between HL and indolent NHL, invasive NHL patients, between B-cell NHL and NK/T-cell NHL patients, and between diffuse large B-cell lymphoma (DLBCL) patients of different stages were analyzed.
  • CONCLUSIONS: 18F-FDG uptake of lymphoma lesions is related to lymphoma invasion, but not related to cell origin and clinical stage.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Hodgkin Disease / metabolism. Lymphoma, Non-Hodgkin / metabolism. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Ki-67 Antigen / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Extranodal NK-T-Cell / metabolism. Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622306.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Barta SK, Yahalom J, Shia J, Hamlin PA: Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma.
  • Paraneoplastic cholestasis is an uncommon presenting symptom in Hodgkin's lymphoma (HL).
  • We report a patient with idiopathic cholestasis and early-stage HL with favorable risk factors whose liver biopsy results were consistent with intrahepatic cholestasis and no ductopenia.
  • The distinction between these 2 diseases has prognostic implications: idiopathic cholestasis is usually reversible in early-stage HL after treatment, whereas patients who develop VBDS commonly die from their disease.
  • We postulate that single-modality radiation therapy alone should be considered a valid treatment alternative in early-stage HL with idiopathic cholestasis.
  • [MeSH-major] Cholestasis / diagnosis. Cholestasis / etiology. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Bile Ducts / pathology. Biopsy. Humans. Jaundice. Liver / pathology. Male. Paraneoplastic Syndromes / metabolism. Positron-Emission Tomography. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Cholestasis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879775.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Wessels G, Bernard Hesseling P: Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa. Transfus Apher Sci; 2005 Feb;32(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
  • Hodgkin's disease (HD) in children corresponds to a large degree to HD in adults.
  • Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.
  • For practical reasons clinicians generally classify and treat NHL in children as either B-cell or T-cell disease.
  • Over the past 22 years, the Paediatric Oncology Unit of the Tygerberg Hospital has treated HD with three different regimens.
  • For the last four years HD has been treated according to the regimen suggested by Schellong with good short term survival rates.
  • BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2).
  • The majority of patients had stage III and IV disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Blood Transfusion. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. South Africa. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737871.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  • [Number-of-references] 15
  •  go-up   go-down


96. Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX: [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage]. Ai Zheng; 2006 Dec;25(12):1543-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
  • BACKGROUND & OBJECTIVE: Nasopharynx is a commonly involved site of non-Hodgkin's lymphoma (NHL), but the differences of clinical characteristics, prognosis, and treatment strategy between B-cell and NK/T-cell nasopharyngeal NHL have seldom been reported.
  • This study was to investigate the clinical manifestations and treatment outcomes of primary B-cell and NK/T-cell nasopharyngeal NHL at early stage, and evaluate the prognostic differences, so as to provide evidences for treatment optimization.
  • METHODS: Clinical data of 80 patients with previously untreated nasopharyngeal NHL at early stage, admitted from May 1987 to Nov.
  • CONCLUSIONS: Among the patients with primary nasopharyngeal NHL at early stage, those with B-cell phenotype may have better prognosis as compared with those with NK/T-cell phenotype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Nasopharyngeal Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Immunophenotyping. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Extranodal NK-T-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166383.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


97. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol; 2005 Feb 20;23(6):1103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
  • PURPOSE: Patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and can be observed without immediate chemotherapy.
  • PATIENTS AND METHODS: Eligible patients had untreated follicular grade 1 NHL, and measurable stage III/IV disease.
  • Fourteen (39%) of 36 patients remain in unmaintained remission, two died without disease progression, and three died with disease progression.
  • Twenty (56%) of 36 patients have disease progression.
  • CONCLUSION: Rituximab can be safely administered to patients with advanced-stage follicular grade 1 NHL with efficacy and minimal toxicity.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease Progression. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Neutropenia / chemically induced. Rituximab. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 20;23(6):1056-8 [15657408.001]
  • (PMID = 15657404.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


98. Kumar R, Sidhu H, Mistry R, Shet T: Primary pulmonary Hodgkin's lymphoma: a rare pitfall in transthoracic fine needle aspiration cytology. Diagn Cytopathol; 2008 Sep;36(9):666-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary Hodgkin's lymphoma: a rare pitfall in transthoracic fine needle aspiration cytology.
  • Primary pulmonary Hodgkin's lymphoma (PPHL) is extremely rare.
  • At an extranodal location such as the lung this lymphoma is likely to be confused with the more commonly occurring carcinomas at this site.
  • In view of the locally advanced stage, patient received a carboplatin and gemcite-based chemotherapy with complete response but postchemotherapy patient refused local surgery.
  • Two years later, the patient developed enlarged nodes which were diagnosed as Hodgkin's lymphoma, and a review of prior lung tumor confirmed the diagnosis of PPHL.
  • [MeSH-major] Diagnostic Errors. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677750.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, Antoniades D: Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar;99(3):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study.
  • OBJECTIVE: Non-Hodgkin's lymphomas (NHL) are the third most common group of malignant lesions in the oral cavity and maxillofacial region.
  • The clinical stage according to the Ann Arbor system was assessed by history, physical, and laboratory examination.
  • At the time of the disease presentation, according to the Ann Arbor system, 11 patients were in stage IE, 2 patients in stage IIE, 2 patients in stage IIIE, 1 patient in stage IVE, and 2 patients in stage IV.
  • According to the Ann Arbor system, the majority of the cases at the time of diagnosis are in stage I or II.
  • Most patients have high grade disease.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716836.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Il'in NV, Nikolaeva EN, Smirnova EV, Vinogradova IuN, Ivanova EI, Izotov BM, Shenderova IA: [20-year experience with modified dose fractionation of radiotherapy in primary Hodgkin's disease]. Vopr Onkol; 2008;54(4):529-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [20-year experience with modified dose fractionation of radiotherapy in primary Hodgkin's disease].
  • Significantly lower frequency of relapse, incidence of pulmonitis and pericarditis, leukopenia and thrombocytopenia stage IV and longer recurrence-free survival were reported after acceleration of multifractionation of STD of 1.35Gy was used for treatment of patients with primary Hodgkin's disease, as compared with standard fractionation.
  • When STD was reduced to 1.2Gy (modified multifractionation), subtotal exposure of lymph nodes was followed by a significant drop in frequency and severity of leukopenia and thrombocytopenia stage III-IV.
  • [MeSH-major] Dose Fractionation. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Aged. Biomedical Research. Disease-Free Survival. Female. Humans. Incidence. Kaplan-Meier Estimate. Leukopenia / epidemiology. Leukopenia / etiology. Male. Middle Aged. Pericarditis / epidemiology. Pericarditis / etiology. Pneumonia / epidemiology. Pneumonia / etiology. Radiotherapy / adverse effects. Recurrence. Retrospective Studies. Russia / epidemiology. Severity of Illness Index. Thrombocytopenia / epidemiology. Thrombocytopenia / etiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942416.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down






Advertisement